Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 200

1.

Apixaban: a novel oral inhibitor of factor Xa.

Nutescu E.

Am J Health Syst Pharm. 2012 Jul 1;69(13):1113-26. doi: 10.2146/ajhp110418. Review.

PMID:
22722590
2.

The role of apixaban for venous and arterial thromboembolic disease.

Prom R, Spinler SA.

Ann Pharmacother. 2011 Oct;45(10):1262-83. doi: 10.1345/aph.1Q119. Epub 2011 Sep 27. Review.

PMID:
21954450
3.

Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery.

Imberti D, Gallerani M, Manfredini R.

J Thromb Thrombolysis. 2012 Aug;34(2):208-13. doi: 10.1007/s11239-012-0716-8.

PMID:
22466929
4.

Apixaban: an oral direct factor-xa inhibitor.

Jiménez D, Yusen RD, Ramacciotti E.

Adv Ther. 2012 Mar;29(3):187-201. doi: 10.1007/s12325-012-0003-2. Epub 2012 Feb 17. Review.

PMID:
22354465
5.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
6.

The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.

Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D.

J Thromb Haemost. 2007 Dec;5(12):2368-75. Epub 2007 Sep 15.

7.

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

APPRAISE Steering Committee and Investigators., Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L.

Circulation. 2009 Jun 9;119(22):2877-85. doi: 10.1161/CIRCULATIONAHA.108.832139. Epub 2009 May 26.

8.

Oral apixaban for the treatment of acute venous thromboembolism.

Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI; AMPLIFY Investigators..

N Engl J Med. 2013 Aug 29;369(9):799-808. doi: 10.1056/NEJMoa1302507. Epub 2013 Jul 1.

9.

The safety and efficacy of apixaban : where do we stand in 2013?

de Souza Brito F, Lopes RD, Alexander JH.

Expert Opin Drug Saf. 2013 Jul;12(4):559-67. doi: 10.1517/14740338.2013.799663. Epub 2013 May 10. Review.

PMID:
23662974
10.

Apixaban: a new factor Xa inhibitor for stroke prevention in patients with nonvalvular atrial fibrillation.

Lam S.

Cardiol Rev. 2013 Jul-Aug;21(4):207-12. doi: 10.1097/CRD.0b013e318293d6e6.

PMID:
23535530
11.

A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects.

Barrett YC, Wang J, Song Y, Pursley J, Wastall P, Wright R, Lacreta F, Frost C.

Thromb Haemost. 2012 May;107(5):916-24. doi: 10.1160/TH11-09-0634. Epub 2012 Mar 8.

PMID:
22398784
12.

Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.

Raskob GE, Gallus AS, Pineo GF, Chen D, Ramirez LM, Wright RT, Lassen MR.

J Bone Joint Surg Br. 2012 Feb;94(2):257-64. doi: 10.1302/0301-620X.94B2.27850.

PMID:
22323697
13.

Apixaban: a new player in the anticoagulant class.

Agrawal R, Jain P, Dikshit SN.

Curr Drug Targets. 2012 Jun;13(6):863-75. Review.

PMID:
22250655
14.

Apixaban: an emerging oral factor Xa inhibitor.

Roser-Jones C, Becker RC.

J Thromb Thrombolysis. 2010 Jan;29(1):141-6. doi: 10.1007/s11239-009-0421-4.

PMID:
19921101
15.

Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery.

Martin MT, Nutescu EA.

Curr Med Res Opin. 2011 Nov;27(11):2123-31. doi: 10.1185/03007995.2011.619178. Epub 2011 Sep 23. Review.

PMID:
21942466
17.

Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.

Botticelli Investigators, Writing Committe., Buller H, Deitchman D, Prins M, Segers A.

J Thromb Haemost. 2008 Aug;6(8):1313-8. doi: 10.1111/j.1538-7836.2008.03054.x. Epub 2008 Jun 6.

18.

Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.

Morell J, Sullivan B, Khalabuda M, McBride BF.

J Clin Pharmacol. 2010 Sep;50(9):986-1000. doi: 10.1177/0091270009355814. Epub 2010 Feb 2.

PMID:
20124518
19.

Apixaban in the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation.

Pujadas-Mestres L, Escolar G, Arellano-Rodrigo E, Galán AM.

Drugs Today (Barc). 2013 Jul;49(7):425-36. doi: 10.1358/dot.2013.49.7.1980498. Review.

PMID:
23914351
20.

Apixaban or enoxaparin for thromboprophylaxis after knee replacement.

Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ.

N Engl J Med. 2009 Aug 6;361(6):594-604. doi: 10.1056/NEJMoa0810773. Erratum in: N Engl J Med. 2009 Oct 29;361(18):1814.

Supplemental Content

Support Center